The study's methodology combined certain keywords, such as "SGLT2 inhibitors and GLP-1 receptor agonists", with "data on stroke", "cerebrovascular events", and "type 2 diabetes". This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.